<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pachyonychia congenita</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pachyonychia congenita</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pachyonychia congenita</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer L Hand, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1096835908"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pachyonychia congenita (PC) is a rare autosomal dominant disorder of keratinization affecting primarily the skin and nails. Typically, severe plantar pain, palmoplantar keratoderma with underlying blisters, and variable hypertrophic nail dystrophy are the predominant distinguishing features. Oral leukokeratosis, cutaneous cysts of various types, and follicular hyperkeratosis are often present. The underlying genetic cause is a mutation in one of five keratin genes: <em>KRT6A</em>, <em>KRT6B</em>, <em>KRT6C</em>, <em>KRT16</em>, or <em>KRT17</em> [<a href="#rid1">1,2</a>].</p><p>The pathogenesis, clinical manifestations, diagnosis, and management of PC are reviewed in this topic. Other disorders of keratinization are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/97333.html" rel="external">"Keratinopathic ichthyoses"</a> and  <a class="medical medical_review" href="/d/html/15471.html" rel="external">"Ichthyosis vulgaris"</a> and  <a class="medical medical_review" href="/d/html/110147.html" rel="external">"Palmoplantar keratoderma"</a> and  <a class="medical medical_review" href="/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses"</a> and  <a class="medical medical_review" href="/d/html/15512.html" rel="external">"Peeling skin syndromes"</a> and  <a class="medical medical_review" href="/d/html/112583.html" rel="external">"Autosomal recessive congenital ichthyoses"</a> and  <a class="medical medical_review" href="/d/html/15472.html" rel="external">"X-linked ichthyosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/97333.html" rel="external">"Keratinopathic ichthyoses"</a> and  <a class="medical medical_review" href="/d/html/15471.html" rel="external">"Ichthyosis vulgaris"</a> and  <a class="medical medical_review" href="/d/html/110147.html" rel="external">"Palmoplantar keratoderma"</a> and  <a class="medical medical_review" href="/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses"</a> and  <a class="medical medical_review" href="/d/html/15512.html" rel="external">"Peeling skin syndromes"</a> and  <a class="medical medical_review" href="/d/html/112583.html" rel="external">"Autosomal recessive congenital ichthyoses"</a> and  <a class="medical medical_review" href="/d/html/15472.html" rel="external">"X-linked ichthyosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/97333.html" rel="external">"Keratinopathic ichthyoses"</a> and  <a class="medical medical_review" href="/d/html/15471.html" rel="external">"Ichthyosis vulgaris"</a> and  <a class="medical medical_review" href="/d/html/110147.html" rel="external">"Palmoplantar keratoderma"</a> and  <a class="medical medical_review" href="/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses"</a> and  <a class="medical medical_review" href="/d/html/15512.html" rel="external">"Peeling skin syndromes"</a> and  <a class="medical medical_review" href="/d/html/112583.html" rel="external">"Autosomal recessive congenital ichthyoses"</a> and  <a class="medical medical_review" href="/d/html/15472.html" rel="external">"X-linked ichthyosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/97333.html" rel="external">"Keratinopathic ichthyoses"</a> and  <a class="medical medical_review" href="/d/html/15471.html" rel="external">"Ichthyosis vulgaris"</a> and  <a class="medical medical_review" href="/d/html/110147.html" rel="external">"Palmoplantar keratoderma"</a> and  <a class="medical medical_review" href="/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses"</a> and  <a class="medical medical_review" href="/d/html/15512.html" rel="external">"Peeling skin syndromes"</a> and  <a class="medical medical_review" href="/d/html/112583.html" rel="external">"Autosomal recessive congenital ichthyoses"</a> and  <a class="medical medical_review" href="/d/html/15472.html" rel="external">"X-linked ichthyosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/97333.html" rel="external">"Keratinopathic ichthyoses"</a> and  <a class="medical medical_review" href="/d/html/15471.html" rel="external">"Ichthyosis vulgaris"</a> and  <a class="medical medical_review" href="/d/html/110147.html" rel="external">"Palmoplantar keratoderma"</a> and  <a class="medical medical_review" href="/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses"</a> and  <a class="medical medical_review" href="/d/html/15512.html" rel="external">"Peeling skin syndromes"</a> and  <a class="medical medical_review" href="/d/html/112583.html" rel="external">"Autosomal recessive congenital ichthyoses"</a> and  <a class="medical medical_review" href="/d/html/15472.html" rel="external">"X-linked ichthyosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/97333.html" rel="external">"Keratinopathic ichthyoses"</a> and  <a class="medical medical_review" href="/d/html/15471.html" rel="external">"Ichthyosis vulgaris"</a> and  <a class="medical medical_review" href="/d/html/110147.html" rel="external">"Palmoplantar keratoderma"</a> and  <a class="medical medical_review" href="/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses"</a> and  <a class="medical medical_review" href="/d/html/15512.html" rel="external">"Peeling skin syndromes"</a> and  <a class="medical medical_review" href="/d/html/112583.html" rel="external">"Autosomal recessive congenital ichthyoses"</a> and  <a class="medical medical_review" href="/d/html/15472.html" rel="external">"X-linked ichthyosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/97333.html" rel="external">"Keratinopathic ichthyoses"</a> and  <a class="medical medical_review" href="/d/html/15471.html" rel="external">"Ichthyosis vulgaris"</a> and  <a class="medical medical_review" href="/d/html/110147.html" rel="external">"Palmoplantar keratoderma"</a> and  <a class="medical medical_review" href="/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses"</a> and  <a class="medical medical_review" href="/d/html/15512.html" rel="external">"Peeling skin syndromes"</a> and  <a class="medical medical_review" href="/d/html/112583.html" rel="external">"Autosomal recessive congenital ichthyoses"</a> and  <a class="medical medical_review" href="/d/html/15472.html" rel="external">"X-linked ichthyosis"</a>.)</p><p></p><p class="headingAnchor" id="H2310506155"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>PC is a rare disease. Its prevalence and incidence are unknown. There are between 1000 to 10,000 cases reported worldwide [<a href="#rid3">3</a>]. As of March 2021, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.pachyonychia.org%2Fpatient-registry%2F&amp;token=f3DNIdk%2F1lHIhjgNfsAlD28ssxb8ZgmRRC0UJX2ZGxWyAen6dw5BXvpE6gsbGVbl3GX61XAf%2FVxDUX31H8a%2FfQ%3D%3D&amp;TOPIC_ID=15504" target="_blank">International Pachyonychia Congenita Research Registry</a> includes 1240 individuals registered with genetically confirmed PC. This is a continually expanding registry of clinical and molecular data from PC patients worldwide. </p><p class="headingAnchor" id="H2806345459"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>Historically, PC was classified into two subtypes: PC-1 (due to variants in <em>KRT6A</em> and <em>KRT16</em>) and PC-2 (due to variants in <em>KRT6B</em> and <em>KRT17</em>). However, molecular and clinical data collected by the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.pachyonychia.org%2Fpatient-registry%2F&amp;token=f3DNIdk%2F1lHIhjgNfsAlD28ssxb8ZgmRRC0UJX2ZGxWyAen6dw5BXvpE6gsbGVbl3GX61XAf%2FVxDUX31H8a%2FfQ%3D%3D&amp;TOPIC_ID=15504" target="_blank">International Pachyonychia Congenita Research Registry</a> showed overlap between these subtypes, leading to a new classification for PC based on molecular analysis [<a href="#rid1">1,4</a>]. Cases with variants in <em>KRT6A</em> are named PC-K6a (MIM #615726), those with variants in <em>KRT6B</em> as PC-K6b (MIM #615728), those with variants in <em>KRT6C</em> as PC-K6c (MIM #615735), those with variants in <em>KRT16</em> as PC-K16 (MIM #167200), and those with <em>KRT17</em> variants are PC-K17 (MIM #167210).</p><p class="headingAnchor" id="H2929064667"><span class="h1">PATHOGENESIS</span></p><p class="headingAnchor" id="H724029824"><span class="h2">Molecular genetics</span><span class="headingEndMark"> — </span>PC is caused by dominant negative variants in <em>KRT6A</em>, <em>KRT6B</em>, <em>KRT6C</em>, <em>KRT16</em>, or <em>KRT17</em>, which encode the keratins K6a, K6b, K6c, K16, and K17, respectively [<a href="#rid2">2,5-7</a>]. PC is inherited as an autosomal dominant trait. Approximately 30 percent of cases are caused by a de novo pathogenic variant. Germline mosaicism is thought to be extremely rare, with only 1 out of 814 cases reported in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.pachyonychia.org%2Fpatient-registry%2F&amp;token=f3DNIdk%2F1lHIhjgNfsAlD28ssxb8ZgmRRC0UJX2ZGxWyAen6dw5BXvpE6gsbGVbl3GX61XAf%2FVxDUX31H8a%2FfQ%3D%3D&amp;TOPIC_ID=15504" target="_blank">International Pachyonychia Congenita Research Registry</a> [<a href="#rid8">8</a>].</p><p>Most variants causing PC are found within the helix boundary domains of <em>KRT6A</em>, <em>KRT6B</em>, <em>KRT6C</em>, <em>KRT16</em>, or <em>KRT17</em>. Disruption to these conserved sequences results in a weakened keratin cytoskeleton and the formation of keratin aggregates. Variants underlying PC are predominantly missense variants, with a smaller number of in-frame insertion/deletion variants, splice-site variants, frameshift variants, and nonsense variants. More than 100 distinct variants have been identified for PC. Many are recurrent variants, and others are "family specific." The most commonly reported variants are K6a p.Asn172del, K16 p.Arg127Cys, K16 p.Asn125Ser, K17 p.Asn92Ser, and K6b p.Glu472Lys [<a href="#rid2">2,9</a>].</p><p>Data suggest that some genetic variants may be predictive of the clinical manifestations of the disease. For example, the <em>KRT16</em> p.L132P variant is associated with younger age of onset, presence of palmar keratoderma, oral leukokeratosis, and a higher number of involved nails. By contrast, other <em>KRT16</em> variants (ie, p.N125S and p.R127C) are associated with a milder phenotype [<a href="#rid10">10</a>]. A missense variant in <em>KRT17</em> has been associated with a dual phenotype of PC and hidradenitis suppurativa in multiple members of a family [<a href="#rid11">11</a>].</p><p>In mice models, elevated oxidative stress due to hypoactive Keap1-Nrf2 signaling, a central regulator of the cellular antioxidant response, appears to have a role in the onset of palmoplantar keratoderma associated with PC [<a href="#rid12">12,13</a>].</p><p class="headingAnchor" id="H925072183"><span class="h2">Keratin expression and function</span><span class="headingEndMark"> — </span>Keratins belong to the family of intermediate filament proteins and are divided into type I (acid) and type II (neutral to basic) keratins. There are 54 known functional keratin genes that are clustered in two chromosomal loci; 28 type I keratins K9 to K40 are located on chromosome 17q21.2, and 26 type II keratins K1 to K8 and K71 to K86 (plus type I keratin K18) are on chromosome 12q13.13 [<a href="#rid14">14,15</a>]. </p><p>Keratins are expressed in a differentiation- and tissue-specific manner, and mutations in many keratins are associated with specific tissue fragility disorders [<a href="#rid9">9,16,17</a>]. The keratins K6a, K6b, K6c, K16, and K17 are normally expressed in the palmoplantar epidermis, nail bed, oral mucosa, hair shaft, and sebaceous glands (ie, the tissues affected in PC). Subtle, phenotypic differences among the subtypes of PC (eg, PC-K16 versus PC-K17) may be due to slightly different expression patterns within these tissues and also to the amount of each of these five genes expressed in these tissues. </p><p>All keratins share a similar protein structure consisting of an alpha helical central rod domain of 310 amino acids subdivided into four domains (1A, 1B, 2A, 2B), which are connected by three nonhelical linker regions (L1, L12, and L2). At either end of the rod domain are short regions that are highly conserved in sequence between each type of keratin; named helix boundary peptides (helix initiation and helix termination), these conserved regions are highly important in end-to-end overlap interactions during keratin filament assembly [<a href="#rid18">18,19</a>]. The rod domain is flanked by head (amino terminal) and tail (carboxy terminal) domains that vary both in size and sequence between keratins.</p><p>During keratin filament assembly, keratins form obligate heterodimers consisting of a type I and type II keratin. The 10 nm keratin filaments form cytoskeletal networks spanning from the nucleus to the plasma membrane, providing structural integrity and flexibility to epidermal cells.</p><p class="headingAnchor" id="H206997226"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H3272259977"><span class="h2">Major features</span><span class="headingEndMark"> — </span>The predominant clinical manifestations of PC seen across all mutation subtypes are a triad of hypertrophic nail dystrophy, plantar keratoderma, and severe plantar pain [<a href="#rid1">1,20-22</a>]. The age of onset of PC is variable, but most cases are clinically apparent soon after birth or during the first few years of life. Adult-onset cases are extremely rare. Many patients have a positive family history for the same disorder.</p><p>Thickening of fingernails and toenails due to hyperkeratosis of the nail bed is usually the first manifestation of PC. It generally presents in the first few months to years of life and can be variable, with some or all nails affected (<a class="graphic graphic_picture graphicRef118654 graphicRef118645 graphicRef118640 graphicRef118643" href="/d/graphic/118654.html" rel="external">picture 1A-D</a>). Affected nails either grow to full length, often with a distally upward slant due to distal hyperkeratosis (<a class="graphic graphic_picture graphicRef52261 graphicRef115343" href="/d/graphic/52261.html" rel="external">picture 2A-B</a>), or the nail plate terminates prematurely, leaving an exposed distal finger (<a class="graphic graphic_picture graphicRef117905" href="/d/graphic/117905.html" rel="external">picture 3</a>). In some patients, nail changes are mild to negligible.</p><p>Plantar keratoderma usually begins when a child starts weight bearing and walking, with diffuse or focal hyperkeratosis of the soles, calluses, and underlying frictional blisters that cause severe pain (<a class="graphic graphic_picture graphicRef118650 graphicRef117900 graphicRef117902" href="/d/graphic/118650.html" rel="external">picture 4A-C</a>). Fissures and open wounds can also be seen. Many patients have also palmar keratoderma (<a class="graphic graphic_picture graphicRef118649" href="/d/graphic/118649.html" rel="external">picture 5</a>).</p><p>Chronic plantar pain may be disabling and has a major impact on quality of life for patients with PC. It can be severe enough to limit mobility and ability to perform daily life activities. It has been hypothesized that plantar pain may have a neuropathic component in these patients [<a href="#rid23">23-25</a>]. </p><p class="headingAnchor" id="H346692299"><span class="h2">Other findings</span><span class="headingEndMark"> — </span>Additional clinical findings that are variably present in patients with PC include oral leukokeratosis, follicular hyperkeratosis on elbows and knees, palmoplantar hyperhidrosis, cutaneous cysts, and natal teeth [<a href="#rid1">1</a>]. </p><p>Oral leukokeratosis presents with white-grayish patches on the tongue and on the cheek mucosa (<a class="graphic graphic_picture graphicRef118647 graphicRef118648 graphicRef117901" href="/d/graphic/118647.html" rel="external">picture 6A-C</a>). In infants, it may cause feeding difficulties. Laryngeal involvement may cause hoarseness and even acute airway obstruction in young children [<a href="#rid26">26,27</a>]. </p><p>Cutaneous cysts, including epidermal inclusion cysts and pilosebaceous cysts such as steatocystomas and vellus hair cysts, typically develop around or after puberty and continue into adulthood (<a class="graphic graphic_picture graphicRef118638 graphicRef118639" href="/d/graphic/118638.html" rel="external">picture 7A-B</a>) [<a href="#rid28">28,29</a>]. They can occur in all subtypes of PC but are particularly common in PC-K17. Depending on their location on the body, cysts can cause pain and discomfort. Milia may occur, particularly on the face of newborns and young children. </p><p>Follicular keratosis may be present on the trunk, elbows, and knees (<a class="graphic graphic_picture graphicRef118642 graphicRef118641 graphicRef117903" href="/d/graphic/118642.html" rel="external">picture 8A-C</a>), particularly at friction points. It usually occurs in childhood/teenage years and lessens during adulthood. </p><p>Excessive sweating of the palms and soles due to palmoplantar hyperhidrosis has been observed in some cases. Palmoplantar hyperhidrosis may underlie the formation of plantar, subepidermal blisters and explain the beneficial effect of botulinum toxin in PC [<a href="#rid30">30</a>]. (See <a class="local">'Management'</a> below.)</p><p>Natal or neonatal teeth (ie, erupted teeth present at birth or by age one month) are sometimes seen in neonates, in particular in those with mutations in <em>KRT17</em> (PC-K17), but it is not a fully penetrant trait. Genetic variants in genes encoding PC-associated keratins may increase susceptibility to tooth decay [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/6276.html" rel="external">"Developmental defects of the teeth", section on 'Natal and neonatal teeth'</a>.)</p><p>Hair abnormalities are exceedingly rare in patients with PC. Generalized alopecia associated with severe manifestations of PC has been reported in a few individuals with homozygous dominant negative mutations in <em>KRT17</em> [<a href="#rid32">32</a>].</p><p>Clinical features of hidradenitis suppurativa have been reported in patients with <em>KRT17</em> variants and, less frequently, in patients with <em>KRT6A</em> and <em>KRT6B</em> variants [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H202525439"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>On histology, prominent ortho- and parakeratosis are seen in skin biopsies taken in areas of plantar hyperkeratosis from patients with PC [<a href="#rid21">21,33,34</a>]. By transmission electron microscopy, bundles of densely aggregated keratin filaments have been observed in the upper spinous layer of PC plantar epidermis [<a href="#rid35">35</a>]. </p><p class="headingAnchor" id="H2150706389"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of PC is usually clinical, based upon the presence of the classic triad of thickened nails, plantar keratoderma, and severe plantar pain and often a family history consistent with an autosomal dominant pattern of inheritance. Nail dystrophy and oral leukokeratosis, which are present at birth or become apparent in the first few months of life, may first suggest the diagnosis [<a href="#rid20">20</a>]. </p><p>The clinical diagnosis can be confirmed by molecular genetic testing and identification of a heterozygous pathogenic variant in one of the five keratin genes (<em>KRT6A</em>, <em>KRT6B</em>, <em>KRT6C</em>, <em>KRT16</em>, or <em>KRT17</em>) associated with PC [<a href="#rid2">2</a>]. </p><p class="headingAnchor" id="H1127509738"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of PC includes a number of genetic syndromes and acquired conditions that share similar clinical features. </p><p class="headingAnchor" id="H451062282"><span class="h2">Clouston syndrome</span><span class="headingEndMark"> — </span>Clouston syndrome (hidrotic ectodermal dysplasia 2; MIM #129500) is an autosomal dominant disorder due to heterozygous mutations in the <em>GJB6</em> (gap junction beta-6) gene that encodes connexin 30 [<a href="#rid36">36-38</a>]. It is characterized by palmoplantar hyperkeratosis (<a class="graphic graphic_picture graphicRef118646" href="/d/graphic/118646.html" rel="external">picture 9</a>) and nail dystrophy that can mimic PC (<a class="graphic graphic_picture graphicRef118653 graphicRef118644" href="/d/graphic/118653.html" rel="external">picture 10A-B</a>). The most useful feature distinguishing Clouston syndrome from PC is variable alopecia (mild to total alopecia), which is relatively common in Clouston syndrome. (See  <a class="medical medical_review" href="/d/html/110146.html" rel="external">"Ectodermal dysplasias", section on 'Ectodermal dysplasia 2, Clouston type'</a>.)</p><p class="headingAnchor" id="H2640912791"><span class="h2">Olmsted syndrome</span><span class="headingEndMark"> — </span>Olmsted syndrome (palmoplantar keratoderma [PPK], mutilating, with periorificial keratotic plaques; MIM #614594) is caused by gain of function mutations in the <em>TRPV3 </em>gene (transient receptor potential cation channel, subfamily V, member 3) [<a href="#rid39">39</a>] and is normally inherited in an autosomal dominant manner [<a href="#rid40">40</a>], although autosomal recessive inheritance can occur [<a href="#rid41">41,42</a>]. An X-linked form of Olmsted syndrome is caused by mutations in the zinc metalloprotease gene, <em>MBTPS2</em> [<a href="#rid43">43</a>]. Individuals present with painful PPK (<a class="graphic graphic_picture graphicRef118651" href="/d/graphic/118651.html" rel="external">picture 11</a> and <a class="graphic graphic_picture graphicRef118652" href="/d/graphic/118652.html" rel="external">picture 12</a>) with lesions that may itch. Sometimes constricting digital bands on hands and feet are present that may lead to spontaneous amputation. Periorificial keratoderma may occur. Abnormalities to the nails include thin nail plates and koilonychia. Hair may be thin, fine, sparse, and slow growing with varying degrees of alopecia, leading in some cases to total alopecia. Milder cases of Olmsted syndrome may be difficult to differentiate from PC [<a href="#rid40">40</a>]. </p><p class="headingAnchor" id="H3553403727"><span class="h2">Palmoplantar keratoderma striata</span><span class="headingEndMark"> — </span>Palmoplantar keratoderma striata (PPKS1; MIM #148700) is an autosomal dominant disorder predominantly caused by heterozygous loss of function mutations (frameshift, splice-site, and nonsense mutations) leading to haploinsufficiency of the <em>DSG1</em> gene [<a href="#rid44">44,45</a>]. A missense mutation in <em>DSG1</em> has also been reported in a case of PPKS1 [<a href="#rid46">46</a>]. There is often marked phenotypic variation both within and among families. A striate pattern of keratoderma on the palms is a distinguishing feature but can be very subtle. There are varying degrees of focal and diffuse plantar keratoderma [<a href="#rid47">47</a>]. Nails are not normally affected, and no other features of PC are present. </p><p class="headingAnchor" id="H1572768187"><span class="h2">Punctate palmoplantar keratoderma type 1</span><span class="headingEndMark"> — </span>Punctate palmoplantar keratoderma type 1 (MIM #148600) is an autosomal dominant disorder due to heterozygous loss of function mutations (frameshift, splice-site, and nonsense mutations) and haploinsufficiency of the alpha- and gamma-adaptin-binding protein gene <em>AAGAB</em> encoding protein p34. Multiple small, hard papules/hyperkeratotic lesions are present on the palms and soles. With age, these lesions increase in number and size and may join together to form larger areas of painful keratoderma with the appearance of focal PPK. The age of onset is generally later than for PC, usually in early adolescence or in adulthood [<a href="#rid48">48,49</a>].</p><p class="headingAnchor" id="H885370010"><span class="h2">Epidermolysis bullosa simplex</span><span class="headingEndMark"> — </span>Epidermolysis bullosa simplex (EBS; MIM #131760, 131800, 131900) is characterized by blisters (within the basal layer of the epidermis) and hyperkeratosis of the palms and soles (<a class="graphic graphic_picture graphicRef117914" href="/d/graphic/117914.html" rel="external">picture 13</a>), but the characteristic nail dystrophy of PC is not normally present. EBS is mostly due to dominant negative mutations in keratins, <em>KRT5</em>, or <em>KRT14</em> [<a href="#rid50">50</a>]. Rare cases of autosomal recessive inheritance have been reported. PC can be mistaken for EBS, particularly in young children, as they are more likely to have blister formation at a young age rather than keratoderma. (See  <a class="medical medical_review" href="/d/html/15449.html" rel="external">"Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features", section on 'Epidermolysis bullosa simplex'</a>.)</p><p class="headingAnchor" id="H4166871958"><span class="h2">Tylosis with esophageal cancer</span><span class="headingEndMark"> — </span>Tylosis with esophageal cancer (MIM #148500), inherited as an autosomal dominant trait, presents with oral leukoplakia, diffuse PPK, and esophageal cancer. Mutations have been identified in the rhomboid protein, iRhom2 (<em>RHBDF2</em>) [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H2971541668"><span class="h2">Dyskeratosis congenita</span><span class="headingEndMark"> — </span>Dyskeratosis congenita is a rare, genetically heterogeneous multisystem disorder that can be inherited as an autosomal dominant, recessive, or X-linked trait [<a href="#rid52">52</a>]. Mutations have been identified in <em>ACD</em>, <em>DKC1</em>, <em>NOLA2</em> (<em>NHP2</em>), <em>NOLA3</em> (<em>NOP10</em>), <em>PARN</em>, <em>RTEL1</em>, <em>TERC</em>, <em>TERT</em>, <em>TINF2</em>, and <em>WRAP53</em>. Reticulate hyperpigmentation, hematologic changes, and squamous cell carcinoma of the skin are common features, but nail dystrophy, oral leukoplakia, and PPK may also be present in some forms. (See  <a class="medical medical_review" href="/d/html/100663.html" rel="external">"Dyskeratosis congenita and other telomere biology disorders"</a>.)</p><p class="headingAnchor" id="H2323460584"><span class="h2">Nonsyndromic congenital nail disorder 10</span><span class="headingEndMark"> — </span>Nonsyndromic congenital nail disorder 10 (MIM #614157) is an autosomal recessive disorder only affecting the nails and caused by biallelic mutations in frizzled 6 (<em>FZD6</em>). Normally, all 20 nails are affected from birth or early childhood by onychauxis (thickening of the nails), onycholysis, and often claw-shaped nails [<a href="#rid53">53-55</a>]. It can be confused with PC, but there is no associated PPK or other features of PC. </p><p class="headingAnchor" id="H3488959252"><span class="h2">Steatocystoma multiplex</span><span class="headingEndMark"> — </span>Steatocystoma multiplex (MIM #184500) is inherited as an autosomal dominant disorder. Widespread multiple cysts occur during puberty and continue into adulthood. Very mild nail changes may be present. It can be associated with mutations in <em>KRT17</em> [<a href="#rid56">56,57</a>]. (See  <a class="medical medical_review" href="/d/html/5573.html" rel="external">"Overview of benign lesions of the skin", section on 'Steatocystoma multiplex'</a>.)</p><p class="headingAnchor" id="H1999757731"><span class="h2">Other</span><span class="headingEndMark"> — </span>Other nail disorders that can be included in the differential diagnosis of PC are: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nail disorder, nonsyndromic congenital 1 (NDNC1)</strong> − NDNC1 (autosomal recessive nail dystrophy; MIM #161050) features early-onset and progressive nail dystrophy inherited in an autosomal recessive fashion and is caused by biallelic mutations in <em>FDZ6</em>, encoding frizzled class receptor 6 [<a href="#rid53">53</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PLACK syndrome</strong> – PLACK (<strong>p</strong>eeling skin, <strong>l</strong>eukonychia, <strong>a</strong>cral punctate keratoses, <strong>c</strong>heilitis, and <strong>k</strong>nuckle pads) syndrome (MIM #616295) is caused by recessive mutations in the <em>CAST</em> gene. PLACK syndrome may be misdiagnosed for PC [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Twenty-nail dystrophy</strong> − Twenty-nail dystrophy (trachyonychia) is a congenital nail disorder that typically affects all 20 nails, with no other associated changes (<a class="graphic graphic_picture graphicRef85528" href="/d/graphic/85528.html" rel="external">picture 14</a> and <a class="graphic graphic_picture graphicRef64919" href="/d/graphic/64919.html" rel="external">picture 15</a>). Autosomal dominance has been reported in some cases. (See  <a class="medical medical_review" href="/d/html/13682.html" rel="external">"Overview of nail disorders", section on 'Trachyonychia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nail psoriasis</strong> − Psoriasis may present with subungual hyperkeratosis involving all or some fingernails and/or toenails (<a class="graphic graphic_picture graphicRef53509" href="/d/graphic/53509.html" rel="external">picture 16</a>). (See  <a class="medical medical_review" href="/d/html/96391.html" rel="external">"Nail psoriasis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Onychomycosis</strong> − Onychomycosis (tinea unguium) is a fungal infection of fingernails and toenails that may present with subungual hyperkeratosis and onycholysis (<a class="graphic graphic_picture graphicRef85579" href="/d/graphic/85579.html" rel="external">picture 17</a> and <a class="graphic graphic_picture graphicRef52455" href="/d/graphic/52455.html" rel="external">picture 18</a>). Onychomycosis typically does not affect all nails and is uncommon in children. (See  <a class="medical medical_review" href="/d/html/4034.html" rel="external">"Onychomycosis: Epidemiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H922459334"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>There is currently no effective or specific therapy for PC. Treatment is mainly directed at reducing nail and palmoplantar hyperkeratosis and controlling pain and should be tailored to the patient's individual needs [<a href="#rid59">59</a>]. Given the rarity of PC, studies evaluating treatment strategies for PC are limited to a few case reports and case series. </p><p class="headingAnchor" id="H1113016269"><span class="h2">Plantar keratoderma</span><span class="headingEndMark"> — </span>Plantar keratoderma is managed by paring/trimming or filing the hyperkeratotic areas either by the patients themselves or a podiatrist [<a href="#rid60">60</a>]. How often this is done varies among patients from every few days to every few weeks. Similarly, the level to which calluses are trimmed is important and patient dependent; leaving a thin layer of callus as opposed to complete trimming appears to result in overall less pain. The skin can be softened by using topical agents, including keratolytics (eg, salicylic acid, urea), moisturizers, and emollients. Some patients find it beneficial to soak the feet prior to paring/trimming. (See  <a class="medical medical_review" href="/d/html/110147.html" rel="external">"Palmoplantar keratoderma", section on 'Management'</a>.)</p><p>Pharmacologic treatments for plantar keratoderma include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral retinoids</strong> – Oral retinoids (<a class="drug drug_general" data-topicid="9250" href="/d/drug information/9250.html" rel="external">acitretin</a> and <a class="drug drug_general" data-topicid="8582" href="/d/drug information/8582.html" rel="external">isotretinoin</a>) are used to treat several hyperkeratotic disorders and may be useful for PC patients to reduce palmoplantar keratoderma (PPK). Data from a retrospective study of 30 patients enrolled in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.pachyonychia.org%2Fpatient-registry%2F&amp;token=f3DNIdk%2F1lHIhjgNfsAlD28ssxb8ZgmRRC0UJX2ZGxWyAen6dw5BXvpE6gsbGVbl3GX61XAf%2FVxDUX31H8a%2FfQ%3D%3D&amp;TOPIC_ID=15504" target="_blank">International Pachyonychia Congenita Research Registry</a> and treated with systemic retinoids indicate that acitretin is more effective than isotretinoin and that low doses (≤25 mg per day) of systemic retinoids are as beneficial as higher doses in thinning plantar calluses and reducing pain [<a href="#rid61">61</a>]. Most patients reported no improvement in nails. </p><p></p><p class="bulletIndent1">Oral retinoids are teratogenic. Extreme caution is recommended for use of <a class="drug drug_general" data-topicid="9250" href="/d/drug information/9250.html" rel="external">acitretin</a> in women of childbearing age and girls prior to childbearing age due to concern for teratogenicity and its longer half-life in comparison with <a class="drug drug_general" data-topicid="8582" href="/d/drug information/8582.html" rel="external">isotretinoin</a>. Pregnancy is contraindicated for <strong>three years</strong> after discontinuing acitretin. (See  <a class="medical medical_review" href="/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris", section on 'Teratogenicity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Botulinum toxin</strong> – In a small number of PC patients, plantar injections of botulinum toxin led to rapid improvement in pain, skin hyperkeratosis, and blistering lasting for several months [<a href="#rid62">62-64</a>]. A validated protocol for botulinum toxin-based treatment of PC-associated pain is now available [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rapamycin (</strong><strong>sirolimus</strong><strong>)</strong> – Oral and topical rapamycin has also shown a beneficial effect in small series of PC patients [<a href="#rid66">66,67</a>]. Definitive proof for a therapeutic effect awaits a formal, randomized, well-controlled trial. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Statins</strong> – Statins have been reported to decrease the expression of KRT6a and, as such, may alleviate the consequences of dominant negative mutations in <em>KRT6A</em>. Accordingly, two case reports described the successful treatment of PC-associated PPK using <a class="drug drug_general" data-topicid="10282" href="/d/drug information/10282.html" rel="external">rosuvastatin</a> [<a href="#rid68">68,69</a>].</p><p></p><p class="headingAnchor" id="H3155858894"><span class="h2">Hyperhidrosis</span><span class="headingEndMark"> — </span>Wicking socks and ventilated footwear can help with increased hyperhidrosis. Plantar injections of botulinum toxin may improve hyperhidrosis as well as pain, hyperkeratosis, and blistering lasting for several months [<a href="#rid62">62-64</a>]. A validated protocol for botulinum toxin-based treatment of PC-associated pain is now available [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H1656023657"><span class="h2">Nail thickening</span><span class="headingEndMark"> — </span>Thickened nails are managed by filing/grinding or clipping using clippers (including pet clippers) and sanders, such as a Dremel tool. Nails can become painful if bacterial or fungal infections occur, and use of antibiotics or antifungals may be required. Surgical removal of nails has been beneficial for some patients, although in many instances the nails have regrown [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H4017545539"><span class="h2">Pain control</span><span class="headingEndMark"> — </span>Pain medication may be necessary for relief of painful plantar keratoderma. Special orthotics, insoles, or cushioned footwear can help reduce the pain. Patients with disabling plantar keratoderma may need to use crutches, canes, or wheelchairs.</p><p class="headingAnchor" id="H861861158"><span class="h2">Cutaneous cysts</span><span class="headingEndMark"> — </span>Cutaneous cysts normally develop around puberty and during adulthood and can be very painful. Cysts may be incised and drained or surgically removed. Infected cysts may require a course of systemic antibiotics. (See  <a class="medical medical_review" href="/d/html/138447.html" rel="external">"Skin abscesses in adults: Treatment", section on 'Indications for antimicrobial therapy'</a>.) </p><p class="headingAnchor" id="H1809664052"><span class="h2">Oral leukokeratosis</span><span class="headingEndMark"> — </span>Good oral hygiene is recommended to improve the appearance of white patches on the tongue and oral mucosa. Young infants with oral leukokeratosis who are failing to thrive can be helped by using a feeding bottle with a soft nipple and an enlarged opening.</p><p class="headingAnchor" id="H399558476"><span class="h1">GENETIC COUNSELING</span><span class="headingEndMark"> — </span>Approximately 30 percent of cases of PC are due to a de novo mutation. Unaffected parents of a child with PC can be reassured about the very low risk of having subsequent affected children, given the extreme rarity of germline mosaicism in unaffected parents [<a href="#rid8">8,22</a>]. There are no reported cases of PC with confirmed molecular testing inherited as an autosomal recessive trait, although semidominance has been reported [<a href="#rid71">71</a>].</p><p>If a parent of a child with PC is also affected, the risk for the siblings is 50 percent. Each child of an individual with PC has a 50 percent risk of inheriting the pathogenetic variant. An updated genetic consultation is recommended prior to childbearing years so that the affected individual can better understand their own reproductive risks and options. Early referral for genetics consultation prior to pregnancy and planning of pregnancies is recommended for couples interested in prenatal diagnosis.</p><p class="headingAnchor" id="H2591947739"><span class="h1">ONLINE RESOURCES</span><span class="headingEndMark"> — </span>Additional information on PC for patients and clinicians is available online at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.pachyonychia.org%2F&amp;token=kgWnuLuwd5ywHVQww%2BY9egolyjZPpG1TPJw61zOMf1mhGB%2FtN40MPjTvfRcNfBqC&amp;TOPIC_ID=15504" target="_blank">Pachyonychia Congenita Project</a>.</p><p class="headingAnchor" id="H314228499"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Pachyonychia congenita (PC) is a rare autosomal dominant disorder characterized by the triad of hypertrophic nail dystrophy, plantar keratoderma with underlying blisters, and severe plantar pain. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PC is caused by dominant negative mutations in one of five keratin genes (<em>KRT6A</em>, <em>KRT6B</em>, <em>KRT6C</em>, <em>KRT16</em>, or <em>KRT17</em>) that define five subtypes of the disease. (See <a class="local">'Molecular genetics'</a> above and <a class="local">'Classification'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thickening of fingernails and toenails is usually the first manifestation of PC and generally presents in the first few months to years of life (<a class="graphic graphic_picture graphicRef52261 graphicRef115343" href="/d/graphic/52261.html" rel="external">picture 2A-B</a>). Plantar keratoderma usually begins when the child starts weight bearing and walking, with diffuse or focal hyperkeratosis of the soles and underlying frictional blisters that cause severe pain (<a class="graphic graphic_picture graphicRef117900 graphicRef117902" href="/d/graphic/117900.html" rel="external">picture 4B-C</a>). Other clinical features include oral leukokeratosis, cutaneous cysts, and follicular hyperkeratosis. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of PC is based upon the clinical findings and a family history consistent with autosomal dominant inheritance. The diagnosis can be confirmed by the presence of a pathogenic mutation by blood test. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is no effective or specific therapy for PC. Treatment is symptomatic and mainly directed at reducing nail and palmoplantar hyperkeratosis and controlling pain. Plantar keratoderma is managed by paring, trimming, or filing the hyperkeratotic plantar areas and thickened nails either by the patients themselves or a podiatrist. Some patients may benefit from treatment with systemic retinoids, although the appropriate dose and duration of treatment have not been determined. (See <a class="local">'Management'</a> above.)</p><p></p><p class="headingAnchor" id="H3306952450"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Eli Sprecher, MD, PhD, and Frances JD Smith, PhD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Eliason MJ, Leachman SA, Feng BJ, et al. A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita. J Am Acad Dermatol 2012; 67:680.</a></li><li><a class="nounderline abstract_t">Wilson NJ, O'Toole EA, Milstone LM, et al. The molecular genetic analysis of the expanding pachyonychia congenita case collection. Br J Dermatol 2014; 171:343.</a></li><li><a class="nounderline abstract_t">Kaspar RL. Challenges in developing therapies for rare diseases including pachyonychia congenita. J Investig Dermatol Symp Proc 2005; 10:62.</a></li><li><a class="nounderline abstract_t">McLean WH, Hansen CD, Eliason MJ, Smith FJ. The phenotypic and molecular genetic features of pachyonychia congenita. J Invest Dermatol 2011; 131:1015.</a></li><li><a class="nounderline abstract_t">Liao H, Sayers JM, Wilson NJ, et al. A spectrum of mutations in keratins K6a, K16 and K17 causing pachyonychia congenita. J Dermatol Sci 2007; 48:199.</a></li><li><a class="nounderline abstract_t">Wilson NJ, Leachman SA, Hansen CD, et al. A large mutational study in pachyonychia congenita. J Invest Dermatol 2011; 131:1018.</a></li><li><a class="nounderline abstract_t">Wilson NJ, Messenger AG, Leachman SA, et al. Keratin K6c mutations cause focal palmoplantar keratoderma. J Invest Dermatol 2010; 130:425.</a></li><li><a class="nounderline abstract_t">Pho LN, Smith FJ, Konecki D, et al. Paternal germ cell mosaicism in autosomal dominant pachyonychia congenita. Arch Dermatol 2011; 147:1077.</a></li><li><a class="nounderline abstract_t">Szeverenyi I, Cassidy AJ, Chung CW, et al. The Human Intermediate Filament Database: comprehensive information on a gene family involved in many human diseases. Hum Mutat 2008; 29:351.</a></li><li><a class="nounderline abstract_t">Samuelov L, Sarig O, Adir N, et al. Identification of clinically useful predictive genetic variants in pachyonychia congenita. Clin Exp Dermatol 2021; 46:867.</a></li><li><a class="nounderline abstract_t">Pavlovsky M, Peled A, Sarig O, et al. Coexistence of pachyonychia congenita and hidradenitis suppurativa: more than a coincidence. Br J Dermatol 2022; 187:392.</a></li><li><a class="nounderline abstract_t">Zieman AG, Coulombe PA. Pathophysiology of pachyonychia congenita-associated palmoplantar keratoderma: new insights into skin epithelial homeostasis and avenues for treatment. Br J Dermatol 2020; 182:564.</a></li><li><a class="nounderline abstract_t">Kerns ML, Hakim JM, Lu RG, et al. Oxidative stress and dysfunctional NRF2 underlie pachyonychia congenita phenotypes. J Clin Invest 2016; 126:2356.</a></li><li><a class="nounderline abstract_t">Moll R, Franke WW, Schiller DL, et al. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31:11.</a></li><li><a class="nounderline abstract_t">Schweizer J, Bowden PE, Coulombe PA, et al. New consensus nomenclature for mammalian keratins. J Cell Biol 2006; 174:169.</a></li><li><a class="nounderline abstract_t">Moll R, Divo M, Langbein L. The human keratins: biology and pathology. Histochem Cell Biol 2008; 129:705.</a></li><li><a class="nounderline abstract_t">Coulombe PA. The Molecular Revolution in Cutaneous Biology: Keratin Genes and their Associated Disease: Diversity, Opportunities, and Challenges. J Invest Dermatol 2017; 137:e67.</a></li><li><a class="nounderline abstract_t">Steinert PM, Marekov LN, Fraser RD, Parry DA. Keratin intermediate filament structure. Crosslinking studies yield quantitative information on molecular dimensions and mechanism of assembly. J Mol Biol 1993; 230:436.</a></li><li><a class="nounderline abstract_t">Parry DA, Strelkov SV, Burkhard P, et al. Towards a molecular description of intermediate filament structure and assembly. Exp Cell Res 2007; 313:2204.</a></li><li><a class="nounderline abstract_t">Shah S, Boen M, Kenner-Bell B, et al. Pachyonychia congenita in pediatric patients: natural history, features, and impact. JAMA Dermatol 2014; 150:146.</a></li><li><a class="nounderline abstract_t">Leachman SA, Kaspar RL, Fleckman P, et al. Clinical and pathological features of pachyonychia congenita. J Investig Dermatol Symp Proc 2005; 10:3.</a></li><li class="breakAll">Smith FJ, Hansen CD, Hull PR, et al. Pachyonychia congenita. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, Seattle, 1993.</li><li><a class="nounderline abstract_t">Brill S, Sprecher E, Smith FJD, et al. Chronic pain in pachyonychia congenita: evidence for neuropathic origin. Br J Dermatol 2018; 179:154.</a></li><li><a class="nounderline abstract_t">Wallis T, Poole CD, Hoggart B. Can skin disease cause neuropathic pain? A study in pachyonychia congenita. Clin Exp Dermatol 2016; 41:26.</a></li><li><a class="nounderline abstract_t">Pan B, Byrnes K, Schwartz M, et al. Peripheral neuropathic changes in pachyonychia congenita. Pain 2016; 157:2843.</a></li><li><a class="nounderline abstract_t">O'Kane AM, Jackson CP, Mahadevan M, Barber C. Laryngeal manifestations of pachyonychia congenita: a clinical case and discussion on management for the otolaryngologist. J Laryngol Otol 2017; 131:S53.</a></li><li><a class="nounderline abstract_t">Haber RM, Drummond D. Pachyonychia congenita with laryngeal obstruction. Pediatr Dermatol 2011; 28:429.</a></li><li><a class="nounderline abstract_t">Takeshita T, Takeshita H, Irie K. Eruptive vellus hair cyst and epidermoid cyst in a patient with pachyonychia congenita. J Dermatol 2000; 27:655.</a></li><li><a class="nounderline abstract_t">Ofaiche J, Duchatelet S, Fraitag S, et al. Familial pachyonychia congenita with steatocystoma multiplex and multiple abscesses of the scalp due to the p.Asn92Ser mutation in keratin 17. Br J Dermatol 2014; 171:1565.</a></li><li><a class="nounderline abstract_t">Goldberg I, Sprecher E, Schwartz ME, Gaitini D. Comparative study of high-resolution multifrequency ultrasound of the plantar skin in patients with various types of hereditary palmoplantar keratoderma. Dermatology 2013; 226:365.</a></li><li><a class="nounderline abstract_t">Duverger O, Carlson JC, Karacz CM, et al. Genetic variants in pachyonychia congenita-associated keratins increase susceptibility to tooth decay. PLoS Genet 2018; 14:e1007168.</a></li><li><a class="nounderline abstract_t">Wilson NJ, Pérez ML, Vahlquist A, et al. Homozygous dominant missense mutation in keratin 17 leads to alopecia in addition to severe pachyonychia congenita. J Invest Dermatol 2012; 132:1921.</a></li><li><a class="nounderline abstract_t">Su WP, Chun SI, Hammond DE, Gordon H. Pachyonychia congenita: a clinical study of 12 cases and review of the literature. Pediatr Dermatol 1990; 7:33.</a></li><li><a class="nounderline abstract_t">Wollina U, Schaarschmidt H, Fünfstück V, Knopf B. Pachyonychia congenita. Immunohistologic findings. Zentralbl Pathol 1991; 137:372.</a></li><li><a class="nounderline abstract_t">McLean WH, Rugg EL, Lunny DP, et al. Keratin 16 and keratin 17 mutations cause pachyonychia congenita. Nat Genet 1995; 9:273.</a></li><li><a class="nounderline abstract_t">Lamartine J, Munhoz Essenfelder G, Kibar Z, et al. Mutations in GJB6 cause hidrotic ectodermal dysplasia. Nat Genet 2000; 26:142.</a></li><li><a class="nounderline abstract_t">van Steensel MA, Jonkman MF, van Geel M, et al. Clouston syndrome can mimic pachyonychia congenita. J Invest Dermatol 2003; 121:1035.</a></li><li><a class="nounderline abstract_t">Hale GI, Wilson NJ, Smith FJ, et al. Mutations in GJB6 causing phenotype resembling pachyonychia congenita. Br J Dermatol 2015; 172:1447.</a></li><li><a class="nounderline abstract_t">Lin Z, Chen Q, Lee M, et al. Exome sequencing reveals mutations in TRPV3 as a cause of Olmsted syndrome. Am J Hum Genet 2012; 90:558.</a></li><li><a class="nounderline abstract_t">Wilson NJ, Cole C, Milstone LM, et al. Expanding the Phenotypic Spectrum of Olmsted Syndrome. J Invest Dermatol 2015; 135:2879.</a></li><li><a class="nounderline abstract_t">Duchatelet S, Guibbal L, de Veer S, et al. Olmsted syndrome with erythromelalgia caused by recessive transient receptor potential vanilloid 3 mutations. Br J Dermatol 2014; 171:675.</a></li><li><a class="nounderline abstract_t">Eytan O, Fuchs-Telem D, Mevorach B, et al. Olmsted syndrome caused by a homozygous recessive mutation in TRPV3. J Invest Dermatol 2014; 134:1752.</a></li><li><a class="nounderline abstract_t">Haghighi A, Scott CA, Poon DS, et al. A missense mutation in the MBTPS2 gene underlies the X-linked form of Olmsted syndrome. J Invest Dermatol 2013; 133:571.</a></li><li><a class="nounderline abstract_t">Armstrong DK, McKenna KE, Purkis PE, et al. Haploinsufficiency of desmoplakin causes a striate subtype of palmoplantar keratoderma. Hum Mol Genet 1999; 8:143.</a></li><li><a class="nounderline abstract_t">Hershkovitz D, Lugassy J, Indelman M, et al. Novel mutations in DSG1 causing striate palmoplantar keratoderma. Clin Exp Dermatol 2009; 34:224.</a></li><li><a class="nounderline abstract_t">Vodo D, O'Toole EA, Malchin N, et al. Striate palmoplantar keratoderma resulting from a missense mutation in DSG1. Br J Dermatol 2018; 179:755.</a></li><li><a class="nounderline abstract_t">Lovgren ML, McAleer MA, Irvine AD, et al. Mutations in desmoglein 1 cause diverse inherited palmoplantar keratoderma phenotypes: implications for genetic screening. Br J Dermatol 2017; 176:1345.</a></li><li><a class="nounderline abstract_t">Pohler E, Mamai O, Hirst J, et al. Haploinsufficiency for AAGAB causes clinically heterogeneous forms of punctate palmoplantar keratoderma. Nat Genet 2012; 44:1272.</a></li><li><a class="nounderline abstract_t">Giehl KA, Herzinger T, Wolff H, et al. Eight Novel Mutations Confirm the Role of AAGAB in Punctate Palmoplantar Keratoderma Type 1 (Buschke-Fischer-Brauer) and Show Broad Phenotypic Variability. Acta Derm Venereol 2016; 96:468.</a></li><li><a class="nounderline abstract_t">Fine JD, Eady RA, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008; 58:931.</a></li><li><a class="nounderline abstract_t">Blaydon DC, Etheridge SL, Risk JM, et al. RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome. Am J Hum Genet 2012; 90:340.</a></li><li><a class="nounderline abstract_t">Ward SC, Savage SA, Giri N, et al. Beyond the triad: Inheritance, mucocutaneous phenotype, and mortality in a cohort of patients with dyskeratosis congenita. J Am Acad Dermatol 2018; 78:804.</a></li><li><a class="nounderline abstract_t">Fröjmark AS, Schuster J, Sobol M, et al. Mutations in Frizzled 6 cause isolated autosomal-recessive nail dysplasia. Am J Hum Genet 2011; 88:852.</a></li><li><a class="nounderline abstract_t">Wilson NJ, Hansen CD, Azkur D, et al. Recessive mutations in the gene encoding frizzled 6 cause twenty nail dystrophy--expanding the differential diagnosis for pachyonychia congenita. J Dermatol Sci 2013; 70:58.</a></li><li><a class="nounderline abstract_t">Kasparis C, Reid D, Wilson NJ, et al. Isolated recessive nail dysplasia caused by FZD6 mutations: report of three families and review of the literature. Clin Exp Dermatol 2016; 41:884.</a></li><li><a class="nounderline abstract_t">Smith FJ, Corden LD, Rugg EL, et al. Missense mutations in keratin 17 cause either pachyonychia congenita type 2 or a phenotype resembling steatocystoma multiplex. J Invest Dermatol 1997; 108:220.</a></li><li><a class="nounderline abstract_t">Covello SP, Smith FJ, Sillevis Smitt JH, et al. Keratin 17 mutations cause either steatocystoma multiplex or pachyonychia congenita type 2. Br J Dermatol 1998; 139:475.</a></li><li><a class="nounderline abstract_t">Haber RM, Rose TH. Identification of a CAST Mutation in a Cohort Previously Misdiagnosed as Having Autosomal Recessive Pachyonychia Congenita. JAMA Dermatol 2015; 151:1393.</a></li><li><a class="nounderline abstract_t">Goldberg I, Fruchter D, Meilick A, et al. Best treatment practices for pachyonychia congenita. J Eur Acad Dermatol Venereol 2014; 28:279.</a></li><li><a class="nounderline abstract_t">Porter RM, Bravo AA, Smith FJD. Management of Plantar KeratodermasLessons from Pachyonychia Congenita. J Am Podiatr Med Assoc 2017; 107:428.</a></li><li><a class="nounderline abstract_t">Gruber R, Edlinger M, Kaspar RL, et al. An appraisal of oral retinoids in the treatment of pachyonychia congenita. J Am Acad Dermatol 2012; 66:e193.</a></li><li><a class="nounderline abstract_t">Swartling C, Vahlquist A. Treatment of pachyonychia congenita with plantar injections of botulinum toxin. Br J Dermatol 2006; 154:763.</a></li><li><a class="nounderline abstract_t">Swartling C, Karlqvist M, Hymnelius K, et al. Botulinum toxin in the treatment of sweat-worsened foot problems in patients with epidermolysis bullosa simplex and pachyonychia congenita. Br J Dermatol 2010; 163:1072.</a></li><li><a class="nounderline abstract_t">González-Ramos J, Sendagorta-Cudós E, González-López G, et al. Efficacy of botulinum toxin in pachyonychia congenita type 1: report of two new cases. Dermatol Ther 2016; 29:32.</a></li><li><a class="nounderline abstract_t">Koren A, Sprecher E, Reider E, Artzi O. A treatment protocol for botulinum toxin injections in the treatment of pachyonychia congenita-associated keratoderma. Br J Dermatol 2020; 182:671.</a></li><li><a class="nounderline abstract_t">Hickerson RP, Leake D, Pho LN, et al. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients. J Dermatol Sci 2009; 56:82.</a></li><li><a class="nounderline abstract_t">Teng JMC, Bartholomew FB, Patel V, Sun G. Novel treatment of painful plantar keratoderma in pachyonychia congenita using topical sirolimus. Clin Exp Dermatol 2018; 43:968.</a></li><li><a class="nounderline abstract_t">Frommherz L, Has C. Successful treatment of Pachyonychia congenita with Rosuvastatin. J Eur Acad Dermatol Venereol 2020; 34:e480.</a></li><li><a class="nounderline abstract_t">Abdollahimajd F, Rajabi F, Shahidi-Dadras M, et al. Pachyonychia congenita: a case report of a successful treatment with rosuvastatin in a patient with a KRT6A mutation. Br J Dermatol 2019; 181:584.</a></li><li><a class="nounderline abstract_t">DeKlotz CMC, Schwartz ME, Milstone LM. Nail removal in pachyonychia congenita: Patient-reported survey outcomes. J Am Acad Dermatol 2017; 76:990.</a></li><li><a class="nounderline abstract_t">Mathews J, Hansen CD, Chandrashekar L. Homozygous dominant missense mutation in Keratin 6b leading to severe pachyonychia congenita. Clin Exp Dermatol 2021; 46:410.</a></li></ol></div><div id="topicVersionRevision">Topic 15504 Version 6.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22264670" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24611874" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The molecular genetic analysis of the expanding pachyonychia congenita case collection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16250210" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Challenges in developing therapies for rare diseases including pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21430705" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The phenotypic and molecular genetic features of pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17719747" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A spectrum of mutations in keratins K6a, K16 and K17 causing pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21326300" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A large mutational study in pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19609311" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Keratin K6c mutations cause focal palmoplantar keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21576551" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Paternal germ cell mosaicism in autosomal dominant pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18033728" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The Human Intermediate Filament Database: comprehensive information on a gene family involved in many human diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33486795" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Identification of clinically useful predictive genetic variants in pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35606927" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Coexistence of pachyonychia congenita and hidradenitis suppurativa: more than a coincidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31021398" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pathophysiology of pachyonychia congenita-associated palmoplantar keratoderma: new insights into skin epithelial homeostasis and avenues for treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27183391" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Oxidative stress and dysfunctional NRF2 underlie pachyonychia congenita phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6186379" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16831889" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : New consensus nomenclature for mammalian keratins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18461349" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The human keratins: biology and pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28411849" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The Molecular Revolution in Cutaneous Biology: Keratin Genes and their Associated Disease: Diversity, Opportunities, and Challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7681879" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Keratin intermediate filament structure. Crosslinking studies yield quantitative information on molecular dimensions and mechanism of assembly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17521629" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Towards a molecular description of intermediate filament structure and assembly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24132595" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pachyonychia congenita in pediatric patients: natural history, features, and impact.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16250204" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical and pathological features of pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16250204" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical and pathological features of pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29210461" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Chronic pain in pachyonychia congenita: evidence for neuropathic origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26358843" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Can skin disease cause neuropathic pain? A study in pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27776012" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Peripheral neuropathic changes in pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27762179" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Laryngeal manifestations of pachyonychia congenita: a clinical case and discussion on management for the otolaryngologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21554383" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pachyonychia congenita with laryngeal obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11092270" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Eruptive vellus hair cyst and epidermoid cyst in a patient with pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24842198" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Familial pachyonychia congenita with steatocystoma multiplex and multiple abscesses of the scalp due to the p.Asn92Ser mutation in keratin 17.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24030314" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Comparative study of high-resolution multifrequency ultrasound of the plantar skin in patients with various types of hereditary palmoplantar keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29357356" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Genetic variants in pachyonychia congenita-associated keratins increase susceptibility to tooth decay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336949" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Homozygous dominant missense mutation in keratin 17 leads to alopecia in addition to severe pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2140447" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pachyonychia congenita: a clinical study of 12 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1722707" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pachyonychia congenita. Immunohistologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7539673" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Keratin 16 and keratin 17 mutations cause pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11017065" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Mutations in GJB6 cause hidrotic ectodermal dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14708603" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clouston syndrome can mimic pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25385569" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Mutations in GJB6 causing phenotype resembling pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22405088" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Exome sequencing reveals mutations in TRPV3 as a cause of Olmsted syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26067147" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Expanding the Phenotypic Spectrum of Olmsted Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24606194" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Olmsted syndrome with erythromelalgia caused by recessive transient receptor potential vanilloid 3 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24463422" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Olmsted syndrome caused by a homozygous recessive mutation in TRPV3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22931912" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A missense mutation in the MBTPS2 gene underlies the X-linked form of Olmsted syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9887343" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Haploinsufficiency of desmoplakin causes a striate subtype of palmoplantar keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19018793" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Novel mutations in DSG1 causing striate palmoplantar keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29315490" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Striate palmoplantar keratoderma resulting from a missense mutation in DSG1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27534273" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Mutations in desmoglein 1 cause diverse inherited palmoplantar keratoderma phenotypes: implications for genetic screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23064416" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Haploinsufficiency for AAGAB causes clinically heterogeneous forms of punctate palmoplantar keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26608363" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Eight Novel Mutations Confirm the Role of AAGAB in Punctate Palmoplantar Keratoderma Type 1 (Buschke-Fischer-Brauer) and Show Broad Phenotypic Variability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18374450" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22265016" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29042228" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Beyond the triad: Inheritance, mucocutaneous phenotype, and mortality in a cohort of patients with dyskeratosis congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21665003" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Mutations in Frizzled 6 cause isolated autosomal-recessive nail dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23374899" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Recessive mutations in the gene encoding frizzled 6 cause twenty nail dystrophy--expanding the differential diagnosis for pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27786367" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Isolated recessive nail dysplasia caused by FZD6 mutations: report of three families and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9008238" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Missense mutations in keratin 17 cause either pachyonychia congenita type 2 or a phenotype resembling steatocystoma multiplex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9767294" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Keratin 17 mutations cause either steatocystoma multiplex or pachyonychia congenita type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26650665" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Identification of a CAST Mutation in a Cohort Previously Misdiagnosed as Having Autosomal Recessive Pachyonychia Congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23363249" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Best treatment practices for pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29077501" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Management of Plantar KeratodermasLessons from Pachyonychia Congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21601946" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : An appraisal of oral retinoids in the treatment of pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16536826" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Treatment of pachyonychia congenita with plantar injections of botulinum toxin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20618323" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Botulinum toxin in the treatment of sweat-worsened foot problems in patients with epidermolysis bullosa simplex and pachyonychia congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26445325" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Efficacy of botulinum toxin in pachyonychia congenita type 1: report of two new cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31127950" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A treatment protocol for botulinum toxin injections in the treatment of pachyonychia congenita-associated keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19699613" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29882237" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Novel treatment of painful plantar keratoderma in pachyonychia congenita using topical sirolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32236980" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Successful treatment of Pachyonychia congenita with Rosuvastatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30307612" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Pachyonychia congenita: a case report of a successful treatment with rosuvastatin in a patient with a KRT6A mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28411774" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Nail removal in pachyonychia congenita: Patient-reported survey outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33301203" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Homozygous dominant missense mutation in Keratin 6b leading to severe pachyonychia congenita.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
